Exscientia Business and Financial Update for the Full Year 2022 OXFORD, U.K. - Exscientia plc (Nasdaq: EXAI) Recent developments in the Company’s pipeline, collaborations, and operations as well as financial results for the fourth quarter and full year 2022 are summarised below. Exscientia will host a conference call today, March 23, at 12:30 p.m. GMT / 8:30 a.m. EDT. "2022 was marked by significant milestones for Exscientia, including signing a groundbreaking strategic collaboration with Sanofi, as we cont ...

公司财务状况 - 公司在2022年12月31日之前的累计总亏损为2.035亿英镑[47] - 公司预计在未来几年将继续遭受重大运营亏损[25] - 公司预计未来需要额外资金来支持持续运营[57] - 公司拥有超过5.058亿英镑的现金、现金等价物和短期银行存款[59] 公司业务风险 - 公司可能需要额外融资，但可能无法以可接受的条件或根本无法筹集到这样的融资[61] - 不利的全球经济和地缘政治条件可能对公司的业务、财务状况或经营业绩产生不利影响[62] - 全球经济和金融市场的一般状况可能对公司的经营业绩产生不利影响，包括通货膨胀和供应中断[63] 技术平台风险 - 公司高度依赖其技术平台来加速药物发现和开发，存在技术平台可能无法发现具有治疗潜力的分子或无法开发出对公司或合作伙伴具有商业可行性的产品的风险[64] - 公司使用其技术平台进行AI实验室实验，技术平台质量和复杂性对公司的研究发现活动、设计和交付有前景的分子候选者以及加速和降低药物发现成本至关重要[65] 临床试验风险 - 公司的药物候选品都处于早期临床开发阶段或临床前开发阶段，如果公司无法推进其药物候选品的临床开发、获得监管批准并最终商业化，或者遇到重大延迟，公司的业务将受到重大损害[67] - 公司已开发的三种药物候选品目前正在临床试验中，但AI尚未开发出任何获批的治疗药物，无法保证任何当前或未来的药物候选品的临床试验将取得成功或产生积极的临床数据[68] 监管风险 - 即使公司获得药物候选品的监管批准，也将面临持续的监管义务和审查，可能导致额外的费用[123] - FDA和其他监管机构的政策可能发生变化，可能会影响公司的药物候选品的监管批准[127] 公司发展战略风险 - 公司可能在未获得美国FDA或其他外国监管机构批准的情况下，在其他国家进行临床试验[115] - 公司可能寻求某些药物候选品的孤儿药物认定，但可能无法获得或维持相关的优惠[116]

Precision Design for Precision Oncology March 2023 Forward-looking statements This presentation and accompanying oral presentation (referred to herein collectively as the "presentation") contain express and implied forwardlooking statements that involve substantial risks and uncertainties. All statements contained in this presentation, other than statements of historical facts, including statements regarding expectations of Exscientia plc ("we," "us", "our," or "Exscientia"), our strategy, future operations ...

Exscientia plc (NASDAQ:EXAI) Q3 2022 Earnings Conference Call November 15, 2022 8:30 AM ET Company Participants Sara Sherman - Vice President-Investor Relations Andrew Hopkins - Chief Executive Officer & Executive Director Ben Taylor - Chief Financial Officer & Chief Strategy Officer Dave Hallett - Chief Operating Officer Mike Krams - Chief Quantitative Medicine Officer Garry Pairaudeau - Chief Technology Officer Conference Call Participants Michael Ryskin - Bank of America Operator Hello, everyone. My name ...

✈ Exscientia 3Q 2022 Business Update November 15, 2022 Forward-looking statements This presentation and accompanying oral presentation (referred to herein collectively as the "presentation") contain express and implied forwardlooking statements that involve substantial risks and uncertainties. All statements contained in this presentation, other than statements of historical facts, including statements regarding expectations of Exscientia plc ("we," "us", "our," or "Exscientia"), our strategy, future operat ...

Exscientia plc (NASDAQ:EXAI) Q2 2022 Earnings Conference Call August 18, 2022 8:30 AM ET Company Participants Sara Sherman - VP, IR Andrew L. Hopkins - Founder and CEO Ben R. Taylor - CFO and Chief Strategy Officer Richard Law - Chief Business Officer David Hallett - COO Garry Pairaudeau - CTO Conference Call Participants Michael Ryskin - Bank of America Merrill Lynch Vikram Purohit - Morgan Stanley Chris Shibutani - Goldman Sachs Group, Inc. Peter Lawson - Barclays Bank PLC Operator Hello, everyone. My nam ...

Exscientia plc (NASDAQ:EXAI) Q1 2022 Earnings Conference Call May 26, 2022 8:30 AM ET Company Participants Sara Sherman - Vice President of Investor Relations Andrew Hopkins - Chief Executive Officer Nikolaus Krall - Vice President of Precision Medicine Ben Taylor - Chief Financial Officer and Chief Strategy Officer Dave Hallett - Chief Operations Officer Conference Call Participants Chris Shibutani - Goldman Sachs Group, Inc. Peter Lawson - Barclays Bank PLC Vikram Purohit - Morgan Stanley Michael Ryskin - ...

� Exscientia Exscientia Technology in Focus March 24, 2022 Safe Harbor Statement This presentation and accompanying oral presentation (referred to herein collectively as the "presentation") contain express and implied forward-looking statements that involve substantial risks and uncertainties. All statements contained in this presentation, other than statements of historical facts, including statements regarding expectations of Exscientia plc ("we," "us", "our," or "Exscientia"), our strategy, future operat ...

Exscientia plc (NASDAQ:EXAI) Q4 2021 Earnings Conference Call March 24, 2022 8:30 AM ET Corporate Participants Sara Sherman - Vice President, Investor Relations Andrew Hopkins - Chief Executive Officer Ben Taylor - Chief Financial Officer and Chief Strategy Officer Dave Hallett - Chief Operations Officer Garry Pairaudeau - Chief Technology Officer Conference Call Participants Michael Ryskin - Bank of America Peter Lawson - Barclays Vikram Purohit - Morgan Stanley Operator Hello, everyone. My name is Chris a ...

Exscientia plc (NASDAQ:EXAI) Q3 2021 Earnings Conference Call November 18, 2021 8:30 AM ET Company Participants Sara Sherman - Vice President, Investor Relations Andrew Hopkins - Chief Executive Officer Ben Taylor - Chief Financial Officer and Chief Strategy Officer Dave Hallett - Chief Operations Officer Garry Pairaudeau - Chief Technology Officer Conference Call Participants Michael Ryskin - Bank of America Vikram Purohit - Morgan Stanley Peter Lawson - Barclays Operator Hello, everyone. My name is Stuart ...